Advanced LifeSciences Confirms Efficacy Of Cethromycin In Second Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Company now intends to focus on filing an NDA in community-acquired pneumonia and seeking a marketing partner for the product.
You may also be interested in...
Advanced Life Sciences’ Cethromycin For CAP Cleared For FDA Submission
Firm plans third quarter NDA for mild-to-moderate community-acquired pneumonia indication.
Advanced Life Sciences’ Cethromycin For CAP Cleared For FDA Submission
Firm plans third quarter NDA for mild-to-moderate community-acquired pneumonia indication.
Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead
Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.